138 related articles for article (PubMed ID: 30279194)
1. Blood-Based Prediction of Tumor Relapse: The cfDNA Forecast.
Siravegna G; Corcoran RB
Cancer Discov; 2018 Oct; 8(10):1213-1215. PubMed ID: 30279194
[No Abstract] [Full Text] [Related]
2. Longitudinal Liquid Biopsy and Mathematical Modeling of Clonal Evolution Forecast Time to Treatment Failure in the PROSPECT-C Phase II Colorectal Cancer Clinical Trial.
Khan KH; Cunningham D; Werner B; Vlachogiannis G; Spiteri I; Heide T; Mateos JF; Vatsiou A; Lampis A; Damavandi MD; Lote H; Huntingford IS; Hedayat S; Chau I; Tunariu N; Mentrasti G; Trevisani F; Rao S; Anandappa G; Watkins D; Starling N; Thomas J; Peckitt C; Khan N; Rugge M; Begum R; Hezelova B; Bryant A; Jones T; Proszek P; Fassan M; Hahne JC; Hubank M; Braconi C; Sottoriva A; Valeri N
Cancer Discov; 2018 Oct; 8(10):1270-1285. PubMed ID: 30166348
[TBL] [Abstract][Full Text] [Related]
3. Genomic Landscape of Cell-Free DNA in Patients with Colorectal Cancer.
Strickler JH; Loree JM; Ahronian LG; Parikh AR; Niedzwiecki D; Pereira AAL; McKinney M; Korn WM; Atreya CE; Banks KC; Nagy RJ; Meric-Bernstam F; Lanman RB; Talasaz A; Tsigelny IF; Corcoran RB; Kopetz S
Cancer Discov; 2018 Feb; 8(2):164-173. PubMed ID: 29196463
[TBL] [Abstract][Full Text] [Related]
4. Circulating DNA and Liquid Biopsies in the Management of Patients with Cancer.
Joosse SA; Pantel K
Cancer Res; 2022 Jun; 82(12):2213-2215. PubMed ID: 35702889
[TBL] [Abstract][Full Text] [Related]
5. Circulating cell-free nucleic acids and platelets as a liquid biopsy in the provision of personalized therapy for lung cancer patients.
Sorber L; Zwaenepoel K; Deschoolmeester V; Van Schil PE; Van Meerbeeck J; Lardon F; Rolfo C; Pauwels P
Lung Cancer; 2017 May; 107():100-107. PubMed ID: 27180141
[TBL] [Abstract][Full Text] [Related]
6. The liquid biopsy in the management of colorectal cancer patients: Current applications and future scenarios.
Normanno N; Cervantes A; Ciardiello F; De Luca A; Pinto C
Cancer Treat Rev; 2018 Nov; 70():1-8. PubMed ID: 30053724
[TBL] [Abstract][Full Text] [Related]
7. Liquid biopsy and PCR-free ultrasensitive detection systems in oncology (Review).
Finotti A; Allegretti M; Gasparello J; Giacomini P; Spandidos DA; Spoto G; Gambari R
Int J Oncol; 2018 Oct; 53(4):1395-1434. PubMed ID: 30085333
[TBL] [Abstract][Full Text] [Related]
8. Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer.
Bauml J; Levy B
Clin Cancer Res; 2018 Sep; 24(18):4352-4354. PubMed ID: 29748181
[TBL] [Abstract][Full Text] [Related]
9. A new approach to epigenome-wide discovery of non-invasive methylation biomarkers for colorectal cancer screening in circulating cell-free DNA using pooled samples.
Gallardo-Gómez M; Moran S; Páez de la Cadena M; Martínez-Zorzano VS; Rodríguez-Berrocal FJ; Rodríguez-Girondo M; Esteller M; Cubiella J; Bujanda L; Castells A; Balaguer F; Jover R; De Chiara L
Clin Epigenetics; 2018; 10():53. PubMed ID: 29686738
[TBL] [Abstract][Full Text] [Related]
10. Liquid Biopsy for Cancer Detection: Clinical and Epidemiologic Considerations.
Wentzensen N; Clarke MA
Clin Cancer Res; 2021 Nov; 27(21):5733-5735. PubMed ID: 34462288
[TBL] [Abstract][Full Text] [Related]
11. A Prospective Evaluation of Circulating Tumor Cells and Cell-Free DNA in EGFR-Mutant Non-Small Cell Lung Cancer Patients Treated with Erlotinib on a Phase II Trial.
Yanagita M; Redig AJ; Paweletz CP; Dahlberg SE; O'Connell A; Feeney N; Taibi M; Boucher D; Oxnard GR; Johnson BE; Costa DB; Jackman DM; Jänne PA
Clin Cancer Res; 2016 Dec; 22(24):6010-6020. PubMed ID: 27281561
[TBL] [Abstract][Full Text] [Related]
12. Clinical validation of prospective liquid biopsy monitoring in patients with wild-type RAS metastatic colorectal cancer treated with FOLFIRI-cetuximab.
Toledo RA; Cubillo A; Vega E; Garralda E; Alvarez R; de la Varga LU; Pascual JR; Sánchez G; Sarno F; Prieto SH; Perea S; Lopéz-Casas PP; López-Ríos F; Hidalgo M
Oncotarget; 2017 May; 8(21):35289-35300. PubMed ID: 27852040
[TBL] [Abstract][Full Text] [Related]
13. An improved digital polymerase chain reaction protocol to capture low-copy KRAS mutations in plasma cell-free DNA by resolving 'subsampling' issues.
Ono Y; Sugitani A; Karasaki H; Ogata M; Nozaki R; Sasajima J; Yokochi T; Asahara S; Koizumi K; Ando K; Hironaka K; Daito T; Mizukami Y
Mol Oncol; 2017 Oct; 11(10):1448-1458. PubMed ID: 28691390
[TBL] [Abstract][Full Text] [Related]
14. Personalized response prediction.
Thoma C
Nat Rev Gastroenterol Hepatol; 2018 Nov; 15(11):657. PubMed ID: 30279467
[No Abstract] [Full Text] [Related]
15. Using circulating cell-free DNA to monitor personalized cancer therapy.
Oellerich M; Schütz E; Beck J; Kanzow P; Plowman PN; Weiss GJ; Walson PD
Crit Rev Clin Lab Sci; 2017 May; 54(3):205-218. PubMed ID: 28393575
[TBL] [Abstract][Full Text] [Related]
16. Liquid biopsy using the supernatant of a pleural effusion for EGFR genotyping in pulmonary adenocarcinoma patients: a comparison between cell-free DNA and extracellular vesicle-derived DNA.
Lee JS; Hur JY; Kim IA; Kim HJ; Choi CM; Lee JC; Kim WS; Lee KY
BMC Cancer; 2018 Dec; 18(1):1236. PubMed ID: 30526536
[TBL] [Abstract][Full Text] [Related]
17. An update on liquid biopsy analysis for diagnostic and monitoring applications in non-small cell lung cancer.
Mayo-de-Las-Casas C; Garzón Ibáñez M; Jordana-Ariza N; García-Peláez B; Balada-Bel A; Villatoro S; Malapelle U; Karachaliou N; Troncone G; Rosell R; Molina-Vila MA
Expert Rev Mol Diagn; 2018 Jan; 18(1):35-45. PubMed ID: 29172773
[TBL] [Abstract][Full Text] [Related]
18. Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients.
Siravegna G; Mussolin B; Buscarino M; Corti G; Cassingena A; Crisafulli G; Ponzetti A; Cremolini C; Amatu A; Lauricella C; Lamba S; Hobor S; Avallone A; Valtorta E; Rospo G; Medico E; Motta V; Antoniotti C; Tatangelo F; Bellosillo B; Veronese S; Budillon A; Montagut C; Racca P; Marsoni S; Falcone A; Corcoran RB; Di Nicolantonio F; Loupakis F; Siena S; Sartore-Bianchi A; Bardelli A
Nat Med; 2015 Jul; 21(7):795-801. PubMed ID: 26030179
[TBL] [Abstract][Full Text] [Related]
19. Moving Forward Liquid Biopsy in Early Liver Cancer Detection.
Rolfo C; Russo A
Cancer Discov; 2023 Mar; 13(3):532-534. PubMed ID: 36855918
[TBL] [Abstract][Full Text] [Related]
20. MET amplification in metastatic colorectal cancer: an acquired response to EGFR inhibition, not a de novo phenomenon.
Raghav K; Morris V; Tang C; Morelli P; Amin HM; Chen K; Manyam GC; Broom B; Overman MJ; Shaw K; Meric-Bernstam F; Maru D; Menter D; Ellis LM; Eng C; Hong D; Kopetz S
Oncotarget; 2016 Aug; 7(34):54627-54631. PubMed ID: 27421137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
